Somatuline Depot (lanreotide prolonged-release subcutaneous) / Teijin, Ipsen 
Welcome,         Profile    Billing    Logout  

23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
2010-023674-39: Evaluation of a treatment regimen for acromegaly

Ongoing
4
100
Europe
Somatuline Autogel, Sandostatin LAR, Dostinex, Somavert, Somatuline Autogel, Sandostatin LAR, Dostinex, Somavert
Österreichisches Akromegalie Register, Österreichisches Akromegalieregister
Acromegaly
 
 
NCT03289741: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Completed
4
53
US
Octreotide, LAR Lanreotide, Questionnaires
Memorial Sloan Kettering Cancer Center
Neuroendocrine Tumors
04/23
04/23
2013-003998-10: A clinical trial investigating the effect of Lanreotide on reducing fistula output in patients with high output enterocutaneous fistula

Ongoing
3/4
40
Europe
Lanreotide autosolution, BIM 23014, Solution for injection/infusion, Somatuline AutoSolution 120 mg
Academic medical center, Academic medical center, Ipsen farmaceuticals
All adult patients with a small bowel fistula with an output > 500ml/day or a an enterostomy with an output > 1500ml/day after gastro-intestinal, abdominal wall surgery. Randomization is possible if patients are at least 4 weeks postoperative and had at least 2 weeks of standard care (loperamide, codeine, PPI)., a highoutput pathway between intestine and the skin, either created by a surgeon or spontaneous after complicated surgery, Diseases [C] - Digestive System Diseases [C06]
 
 
2010-022572-32: Invloed van Somatuline® autogel 120mg op post-operatieve drainage na TME-chirurgie voor rectumcarcinoom

Ongoing
3
50
Europe
somatuline, Solution for injection, Somatuline 120 mg
Ghent University Hospital, Ipsen NV
Patiënten die een rectumresectie ondergaan voor rectumcarcinoom., Patiënten die een rectumresectie ondergaan voor rectumcarcinoom, Body processes [G] - Biological Phenomena [G16]
 
 
2022-000507-12: A randomized, controlled, open-label study of RYZ101 compared with standard of care therapy in subjects with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following 177Lu SSA therapy Ensayo aleatorizado, controlado y abierto de RYZ101 frente al tratamiento habitual en sujetos con tumores neuroendocrinos gastroenteropancreáticos bien diferenciados SSTR+, avanzados e inoperables, que hayan progresado tras tratamiento con 177Lu SSA.

Not yet recruiting
3
288
Europe
RYZ101, Sunitinib, RYZ101, Sunitinib, L01XE04, Solution for injection, Tablet, Capsule, hard, Powder and solvent for suspension for injection, Solution for injection in pre-filled syringe, Everolimus Zentiva 5mg Tabletten, Szunitinib Mylan 12,5 mg, Sandostatin® LAR®- Monatsdepot 30 mg powder and solvent for suspension for injection, SOMATULINE AUTOGEL 120 mg solution for injection in a pre-filled syringe, Szunitinib Sandoz 12,5 mg
RayzeBio, Inc., RayzeBio, Inc.
gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, Diseases [C] - Cancer [C04]
 
 
NCT06807437: Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Not yet recruiting
3
274
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Distal Pancreatectomy, Lanreotide, Angiopeptin, BIM-23014, DC 13116, Dermopeptin, Ipstyl, Somatulina, Somatuline, Questionnaire Administration, Saline, ISOTONIC SODIUM CHLORIDE SOLUTION, Normal Saline, Sodium Chloride 0.9%
SWOG Cancer Research Network, National Cancer Institute (NCI)
Pancreatic Carcinoma, Pancreatic Neoplasm
11/27
11/27
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
SORENTO, NCT05050942 / 2021-000849-40: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET

Active, not recruiting
3
332
Europe, Canada, US, RoW
CAM2029, Octreotide LAR, Lanreotide ATG
Camurus AB, Camurus AB
Gastro-enteropancreatic Neuroendocrine Tumor
12/25
12/27
2009-012981-30: Prospective study to assess the efficacy and safety of lanreotide 120 mg as treatment of clinical symptoms associated with inoperable intestinal obstruction

Ongoing
2
40
Europe
Lanreotide, Solution for injection, Somatuline Autogel Injectable
University Hospital Ghent
Inoperable malignant bowel obstruction
 
 
2011-003687-78: Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) LANREOTIDE AUTOGEL NELTRATTAMENTO DEI PAZIENTI CON FIBROSI POLMONARE IDIOPATICA

Ongoing
2
10
Europe
Gallium68-Dota-Noc, NA, Solution for injection
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI, IPSEN
Idiopathic Pulmonary Fibrosis Fibrosi polmonare interstiziale idiopatica, Idiopathic Pulmonary Fibrosis Fibrosi polmonare interstiziale idiopatica, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2013-004232-29: The effect of lanreotide on therapy resistant gastro-esophageal reflux

Ongoing
2
15
Europe
lanreotide autogel 120 mg, H01CB03, Gel for injection, Somatuline Autogel Injectable 120 mg
UZ Brussel, IPSEN NV
patients with persistent endoscopic reflux in spite of maximal medical therapy with PPI 2 x 40 mg pantoprazole before breakfast and dinner and 300 mg of H2 blocker ranitidine at bedtime AND continuing pathological reflux proven on impedancemetry., Persistent therapy resistant gastric esophageal reflux, Diseases [C] - Digestive System Diseases [C06]
 
 
2005-004300-36: Use of somatostatin analogue therapy as primary medical treatment of acromegaly

Ongoing
2
10
Europe
Somatuline Autogel, Somatuline Autogel 60mg, Somatuline Autogel 90mg, Somatuline Autogel 120mg, Somatuline Autogel 60mg, Somatuline Autogel 90mg, Somatuline Autogel 120mg
Plymouth Hospital NHS Trust, R&D dept
Acromegaly
 
 
2009-016082-29: Role of Lanreotide in the Management of Paraduodenal Pancreatitis

Ongoing
2
60
Europe
Somatuline Autogel 90 mg, Somatuline Autogel 90 mg
Erasme hospital
Paraduodenal pancreatitis
 
 
2015-004626-34: NA NA

Ongoing
2
20
Europe
Metformina TEVA, IPSTYL, [Metformina], [IPSTYL], Tablet, Powder and solvent for solution for injection, METFORMINA TEVA - 30 CPR RIVESTITE IN BLISTER BIANCO OPACO PVC/PVDC/AL DA 850 MG, IPSTYL - 30 MG/2 ML POLVERE E SOLVENTE PER SOSPENSIONE INIETTABILE A RILASCIO PROLUNGATO PER USO INTRAMUSCOLARE1 FLACONE POLVERE + 1 FIALA SOLVENTE 2 ML
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", IPSEN S.P.A.
Patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids. Tumore neuroendocrino gastro-intestinale (GI) o carcinoide polmonare ben differenziato in stadio avanzato e/o non resecabile, Advanced neuroendocrine tumor Tumore neuroendocrino in stadio avanzato, Diseases [C] - Hormonal diseases [C19]
 
 
LAMPARA, NCT03946527: LAnreotide in Metastatic Pheochromocytoma / PARAganglioma

Active, not recruiting
2
10
US
Lanreotide, Somatuline Depot
Antonio Fojo, Ipsen
Paraganglioma, Pheochromocytoma
03/26
03/26
NCT05048901: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Recruiting
1/2
49
RoW
Cabozantinib, Cabometyx, Lanreotide, Somatuline
National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Tri-Service General Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital
Neuroendocrine Tumors,Gastroenteropancreatic
08/26
12/26
ACTRN12620001261909p: A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteers

Not yet recruiting
1
16
 
Ascil Australia Pty LTD, Ascil Australia Pty LTD
Acromegaly; Neuroendocrine Tumours
 
 
ACTRN12620001261909: A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteers

Recruiting
1
16
 
Ascil Australia Pty LTD, Ascil Australia Pty LTD
Acromegaly, Neuroendocrine Tumours
 
 
MetNET-2, NCT02823691: The Trial

Active, not recruiting
1
20
Europe
Lanreotide and Metformin, Ipstyl and Metformin
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Neuroendocrine Tumors
12/21
12/21
OXTEND-01, NCT05364944: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Terminated
1
20
Europe, RoW
Debio 4126, Sandostatin LAR, Octreotide acetate, Somatuline ATG, Lanreotide acetate
Debiopharm International SA
Acromegaly, GEP-NET
10/24
12/24
ACRO-SSA, NCT06607666: Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands

Completed
N/A
102
Europe
Lanreotide autogel, Somatostatin Receptor ligand
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Acromegaly
01/24
07/24
AIM-NETs, NCT04696042: Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

Completed
N/A
71
RoW
Lanreotide autogel
Asan Medical Center, Samsung Medical Center, Seoul St. Mary's Hospital, Severance Hospital, Seoul National University Bundang Hospital
Neuroendocrine Tumors
01/24
01/25
NCT05431803: Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Completed
N/A
129
RoW
Ipsen
Acromegaly
12/24
12/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
2010-023674-39: Evaluation of a treatment regimen for acromegaly

Ongoing
4
100
Europe
Somatuline Autogel, Sandostatin LAR, Dostinex, Somavert, Somatuline Autogel, Sandostatin LAR, Dostinex, Somavert
Österreichisches Akromegalie Register, Österreichisches Akromegalieregister
Acromegaly
 
 
NCT03289741: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Completed
4
53
US
Octreotide, LAR Lanreotide, Questionnaires
Memorial Sloan Kettering Cancer Center
Neuroendocrine Tumors
04/23
04/23
2013-003998-10: A clinical trial investigating the effect of Lanreotide on reducing fistula output in patients with high output enterocutaneous fistula

Ongoing
3/4
40
Europe
Lanreotide autosolution, BIM 23014, Solution for injection/infusion, Somatuline AutoSolution 120 mg
Academic medical center, Academic medical center, Ipsen farmaceuticals
All adult patients with a small bowel fistula with an output > 500ml/day or a an enterostomy with an output > 1500ml/day after gastro-intestinal, abdominal wall surgery. Randomization is possible if patients are at least 4 weeks postoperative and had at least 2 weeks of standard care (loperamide, codeine, PPI)., a highoutput pathway between intestine and the skin, either created by a surgeon or spontaneous after complicated surgery, Diseases [C] - Digestive System Diseases [C06]
 
 
2010-022572-32: Invloed van Somatuline® autogel 120mg op post-operatieve drainage na TME-chirurgie voor rectumcarcinoom

Ongoing
3
50
Europe
somatuline, Solution for injection, Somatuline 120 mg
Ghent University Hospital, Ipsen NV
Patiënten die een rectumresectie ondergaan voor rectumcarcinoom., Patiënten die een rectumresectie ondergaan voor rectumcarcinoom, Body processes [G] - Biological Phenomena [G16]
 
 
2022-000507-12: A randomized, controlled, open-label study of RYZ101 compared with standard of care therapy in subjects with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following 177Lu SSA therapy Ensayo aleatorizado, controlado y abierto de RYZ101 frente al tratamiento habitual en sujetos con tumores neuroendocrinos gastroenteropancreáticos bien diferenciados SSTR+, avanzados e inoperables, que hayan progresado tras tratamiento con 177Lu SSA.

Not yet recruiting
3
288
Europe
RYZ101, Sunitinib, RYZ101, Sunitinib, L01XE04, Solution for injection, Tablet, Capsule, hard, Powder and solvent for suspension for injection, Solution for injection in pre-filled syringe, Everolimus Zentiva 5mg Tabletten, Szunitinib Mylan 12,5 mg, Sandostatin® LAR®- Monatsdepot 30 mg powder and solvent for suspension for injection, SOMATULINE AUTOGEL 120 mg solution for injection in a pre-filled syringe, Szunitinib Sandoz 12,5 mg
RayzeBio, Inc., RayzeBio, Inc.
gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, Diseases [C] - Cancer [C04]
 
 
NCT06807437: Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Not yet recruiting
3
274
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Distal Pancreatectomy, Lanreotide, Angiopeptin, BIM-23014, DC 13116, Dermopeptin, Ipstyl, Somatulina, Somatuline, Questionnaire Administration, Saline, ISOTONIC SODIUM CHLORIDE SOLUTION, Normal Saline, Sodium Chloride 0.9%
SWOG Cancer Research Network, National Cancer Institute (NCI)
Pancreatic Carcinoma, Pancreatic Neoplasm
11/27
11/27
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
SORENTO, NCT05050942 / 2021-000849-40: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET

Active, not recruiting
3
332
Europe, Canada, US, RoW
CAM2029, Octreotide LAR, Lanreotide ATG
Camurus AB, Camurus AB
Gastro-enteropancreatic Neuroendocrine Tumor
12/25
12/27
2009-012981-30: Prospective study to assess the efficacy and safety of lanreotide 120 mg as treatment of clinical symptoms associated with inoperable intestinal obstruction

Ongoing
2
40
Europe
Lanreotide, Solution for injection, Somatuline Autogel Injectable
University Hospital Ghent
Inoperable malignant bowel obstruction
 
 
2011-003687-78: Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) LANREOTIDE AUTOGEL NELTRATTAMENTO DEI PAZIENTI CON FIBROSI POLMONARE IDIOPATICA

Ongoing
2
10
Europe
Gallium68-Dota-Noc, NA, Solution for injection
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI, IPSEN
Idiopathic Pulmonary Fibrosis Fibrosi polmonare interstiziale idiopatica, Idiopathic Pulmonary Fibrosis Fibrosi polmonare interstiziale idiopatica, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2013-004232-29: The effect of lanreotide on therapy resistant gastro-esophageal reflux

Ongoing
2
15
Europe
lanreotide autogel 120 mg, H01CB03, Gel for injection, Somatuline Autogel Injectable 120 mg
UZ Brussel, IPSEN NV
patients with persistent endoscopic reflux in spite of maximal medical therapy with PPI 2 x 40 mg pantoprazole before breakfast and dinner and 300 mg of H2 blocker ranitidine at bedtime AND continuing pathological reflux proven on impedancemetry., Persistent therapy resistant gastric esophageal reflux, Diseases [C] - Digestive System Diseases [C06]
 
 
2005-004300-36: Use of somatostatin analogue therapy as primary medical treatment of acromegaly

Ongoing
2
10
Europe
Somatuline Autogel, Somatuline Autogel 60mg, Somatuline Autogel 90mg, Somatuline Autogel 120mg, Somatuline Autogel 60mg, Somatuline Autogel 90mg, Somatuline Autogel 120mg
Plymouth Hospital NHS Trust, R&D dept
Acromegaly
 
 
2009-016082-29: Role of Lanreotide in the Management of Paraduodenal Pancreatitis

Ongoing
2
60
Europe
Somatuline Autogel 90 mg, Somatuline Autogel 90 mg
Erasme hospital
Paraduodenal pancreatitis
 
 
2015-004626-34: NA NA

Ongoing
2
20
Europe
Metformina TEVA, IPSTYL, [Metformina], [IPSTYL], Tablet, Powder and solvent for solution for injection, METFORMINA TEVA - 30 CPR RIVESTITE IN BLISTER BIANCO OPACO PVC/PVDC/AL DA 850 MG, IPSTYL - 30 MG/2 ML POLVERE E SOLVENTE PER SOSPENSIONE INIETTABILE A RILASCIO PROLUNGATO PER USO INTRAMUSCOLARE1 FLACONE POLVERE + 1 FIALA SOLVENTE 2 ML
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", IPSEN S.P.A.
Patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids. Tumore neuroendocrino gastro-intestinale (GI) o carcinoide polmonare ben differenziato in stadio avanzato e/o non resecabile, Advanced neuroendocrine tumor Tumore neuroendocrino in stadio avanzato, Diseases [C] - Hormonal diseases [C19]
 
 
LAMPARA, NCT03946527: LAnreotide in Metastatic Pheochromocytoma / PARAganglioma

Active, not recruiting
2
10
US
Lanreotide, Somatuline Depot
Antonio Fojo, Ipsen
Paraganglioma, Pheochromocytoma
03/26
03/26
NCT05048901: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Recruiting
1/2
49
RoW
Cabozantinib, Cabometyx, Lanreotide, Somatuline
National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Tri-Service General Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital
Neuroendocrine Tumors,Gastroenteropancreatic
08/26
12/26
ACTRN12620001261909p: A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteers

Not yet recruiting
1
16
 
Ascil Australia Pty LTD, Ascil Australia Pty LTD
Acromegaly; Neuroendocrine Tumours
 
 
ACTRN12620001261909: A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteers

Recruiting
1
16
 
Ascil Australia Pty LTD, Ascil Australia Pty LTD
Acromegaly, Neuroendocrine Tumours
 
 
MetNET-2, NCT02823691: The Trial

Active, not recruiting
1
20
Europe
Lanreotide and Metformin, Ipstyl and Metformin
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Neuroendocrine Tumors
12/21
12/21
OXTEND-01, NCT05364944: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Terminated
1
20
Europe, RoW
Debio 4126, Sandostatin LAR, Octreotide acetate, Somatuline ATG, Lanreotide acetate
Debiopharm International SA
Acromegaly, GEP-NET
10/24
12/24
ACRO-SSA, NCT06607666: Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands

Completed
N/A
102
Europe
Lanreotide autogel, Somatostatin Receptor ligand
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Acromegaly
01/24
07/24
AIM-NETs, NCT04696042: Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

Completed
N/A
71
RoW
Lanreotide autogel
Asan Medical Center, Samsung Medical Center, Seoul St. Mary's Hospital, Severance Hospital, Seoul National University Bundang Hospital
Neuroendocrine Tumors
01/24
01/25
NCT05431803: Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Completed
N/A
129
RoW
Ipsen
Acromegaly
12/24
12/24

Download Options